Ceftaroline fosamil and NXL104 (q8h)
Drug600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 8 hours (q8h);
Other names: Ceftaroline fosamil and Avibactam(NXL104) (q8h)
NCT Number: NCT01281462
This is a study in adult subjects with complicated urinary tract infection (cUTI) comparing treatment with intravenous (IV) coadministered ceftaroline fosamil and NXL104 versus treatment with IV doripenem.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Investigational Site, Plovdiv, Bulgaria
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Subjects must meet the following inclusion criteria:
Exclusion criteria
Subjects must NOT meet any of the following exclusion criteria:
600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 8 hours (q8h);
Other names: Ceftaroline fosamil and Avibactam(NXL104) (q8h)
600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 12 hours (q12h);
Other names: Ceftaroline fosamil and Avibactam(NXL104) (q12h)
500 mg doripenem IV q8h;
On CXL-MD-02, there were (3) treatment arms (meaning a subject could be randomized to 1 of 3 possible treatment regimens). Each treatment arm contained 1 or 2 placebo doses of IV saline in order to preserve the blind.
Other names: placebo (saline)
Time frame: 5 to 11 days after last dose of study drug
The number and percentage of subjects in each treatment group recorded as having a favorable microbiological response in the ME Population at Test-of-Cure (TOC)
Time frame: from administration of first dose of study drug to the Late -Follow -Up (LFU) visit (28 to 42 days after administration of the last dose of study drug)
Evaluate the safety of coadministered IV ceftaroline fosamil and NXL104 in subjects with cUTI. Summaries of AEs, SAEs, deaths, laboratory evaluations (hematology and coagulation studies, comprehensive metabolic panel, and urinalysis), vital signs, ECGs, and physical examinations will be provided for each treatment group.
Time frame: 5 to 11 days after last dose of study drug
The number and percentage of subjects in each treatment group classified as clinical cure Clinically Evaluable (CE) Population at TOC
Forest Laboratories
Industry
A Phase 2, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Coadministered Ceftaroline Fosamil and NXL104 Versus Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infection
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07627412
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Nanjing, Jiangsu, China
View Trial DetailsNCT06801405
Acute Kidney Injury, Antibiotic Prophylaxis
Jales, São Paulo, Brazil
View Trial DetailsNCT05319561
Common Infections, Female Urogenital Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT07438184
Chronic Prostatitis (CP), Female Urogenital Diseases
Salamanca, Spain
View Trial Details